Biocon has completed the acquisition of the remaining equity shares of its unlisted subsidiary Biocon Biologics from Mylan Inc for $200 million, taking its total stake in Biocon Biologics to about 98% on a fully diluted basis.
Biocon has completed the acquisition of the remaining equity shares of its unlisted subsidiary Biocon Biologics from Mylan Inc for $200 million, taking its total stake in Biocon Biologics to about 98% on a fully diluted basis.